Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Irhythm - The Untold Story

iRhythm Technologies Touts Medicare Win, Zio Growth and AI-Driven Margin Gains

iRhythm Technologies (NASDAQ:IRTC) executives said the company is seeing continued business momentum after a favorable Medicare coverage update, a stronger-than-expected first quarter and progress on several product and margin initiatives. Speaking at an investor event, Stephanie Zhadkevich, senior

MarketBeat · May 18

Investor Short Report Flags Steep Downside Risk For iRhythm Technologies (CORRECTED)

Editor's Note: An earlier version misstated that iRhythm had not responded; the company provided a statement on Aug. 18.

Benzinga · Aug 18, 2025

2 Potential Stocks to Buy From Barchart’s ‘Death Cross’ Indicator

While a security’s short-term moving average dipping below its long-term average warrants caution, this dynamic may also be a contrarian indicator.

Barchart · Jun 28, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

Benzinga · Jul 22, 2022

Investors Cheer Revised, Better Than Expected iRhythm's FY22 Outlook

iRhythm Technologies Inc (NASDAQ:IRTC) posted Q1 sales of $92.4 million, up 24.3% Y/Y, beating the consensus of $86.76 million. The developer of remote external electrocardiogram monitors reported an adjusted EPS loss of $(0.80), above the consensus of $(1.08). “Our strong first-quarter results are indicative of the momentum we carried into 2022 with an…

Benzinga · May 6, 2022

AI device cuts waiting times for heart patients to 'matter of days'

New technology tested on patients in Liverpool has provided dramatic results

Liverpool Echo · Apr 4, 2022

Down More Than 55% From Their 2020 Highs, is Now a Good Time to Buy Telehealth Stocks Teladoc, iRhythm, and American Well?

As the COVID-19 pandemic has rampaged around the world, telehealth has burst onto the scene as a lifeline to individuals who require medical help. However, with most of the U.S. population having now received COVID-19 vaccinations, more people are resuming outdoor activities, resulting in a decline in the growth of…

StockNews.com · Jan 27, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Organisations

European Medicines Agency

Rhythm Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.